CL2007001405A1 - Compuesto correspondiente a (2r)-5 -[5-(morfolin-4-ilmetil)-3-furil]-3 h-espiro[4-azabiciclo[2.2.2]octano-2,2 -furo[2,3-b]piridina], ligando del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso para el tratamiento de la ansiedad, esquizofrenia, alzheimer, adiccion a nicotina, parkinson, entre otras. - Google Patents

Compuesto correspondiente a (2r)-5 -[5-(morfolin-4-ilmetil)-3-furil]-3 h-espiro[4-azabiciclo[2.2.2]octano-2,2 -furo[2,3-b]piridina], ligando del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso para el tratamiento de la ansiedad, esquizofrenia, alzheimer, adiccion a nicotina, parkinson, entre otras.

Info

Publication number
CL2007001405A1
CL2007001405A1 CL2007001405A CL2007001405A CL2007001405A1 CL 2007001405 A1 CL2007001405 A1 CL 2007001405A1 CL 2007001405 A CL2007001405 A CL 2007001405A CL 2007001405 A CL2007001405 A CL 2007001405A CL 2007001405 A1 CL2007001405 A1 CL 2007001405A1
Authority
CL
Chile
Prior art keywords
schizophrenia
anxiety
parkinson
alzheimer
pharmaceutical composition
Prior art date
Application number
CL2007001405A
Other languages
English (en)
Spanish (es)
Inventor
James Woods
Rebecca Urbanek
Hui-Fang Chang
Hui Xiong
Christopher Holmquist
Timothy PISER
Thomas Simpson
Phi
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38694158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007001405(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2007001405A1 publication Critical patent/CL2007001405A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2007001405A 2006-05-17 2007-05-16 Compuesto correspondiente a (2r)-5 -[5-(morfolin-4-ilmetil)-3-furil]-3 h-espiro[4-azabiciclo[2.2.2]octano-2,2 -furo[2,3-b]piridina], ligando del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso para el tratamiento de la ansiedad, esquizofrenia, alzheimer, adiccion a nicotina, parkinson, entre otras. CL2007001405A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74747606P 2006-05-17 2006-05-17
US82497506P 2006-09-08 2006-09-08

Publications (1)

Publication Number Publication Date
CL2007001405A1 true CL2007001405A1 (es) 2008-01-25

Family

ID=38694158

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007001405A CL2007001405A1 (es) 2006-05-17 2007-05-16 Compuesto correspondiente a (2r)-5 -[5-(morfolin-4-ilmetil)-3-furil]-3 h-espiro[4-azabiciclo[2.2.2]octano-2,2 -furo[2,3-b]piridina], ligando del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso para el tratamiento de la ansiedad, esquizofrenia, alzheimer, adiccion a nicotina, parkinson, entre otras.

Country Status (19)

Country Link
US (2) US7842803B2 (https=)
EP (1) EP2019831B1 (https=)
JP (1) JP2009537517A (https=)
KR (1) KR20090007753A (https=)
AR (1) AR060914A1 (https=)
AU (1) AU2007250560B2 (https=)
BR (1) BRPI0711941A2 (https=)
CA (1) CA2652610A1 (https=)
CL (1) CL2007001405A1 (https=)
EC (1) ECSP088971A (https=)
ES (1) ES2392997T3 (https=)
IL (1) IL195019A0 (https=)
MX (1) MX2008014436A (https=)
NO (1) NO20084915L (https=)
RU (1) RU2441007C2 (https=)
SA (1) SA07280244B1 (https=)
TW (1) TW200813067A (https=)
UY (1) UY30349A1 (https=)
WO (1) WO2007133155A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
WO2009066107A1 (en) * 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
WO2012101060A1 (en) 2011-01-27 2012-08-02 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
AU2012232711B2 (en) 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
ES2776996T3 (es) 2011-10-20 2020-08-03 Novartis Ag Biomarcadores predictivos de la sensibilidad al tratamiento por el activador del receptor de la acetilcolina nicotínico alfa 7
CN104837499B (zh) 2012-12-11 2018-02-23 诺华有限公司 预测对α7烟碱型乙酰胆碱受体激活剂治疗响应性的生物标志物
MX362819B (es) 2013-01-15 2019-02-18 Novartis Ag Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.
JP6338223B2 (ja) 2013-01-15 2018-06-06 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
KR101879919B1 (ko) 2013-01-15 2018-07-18 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도
WO2017156309A1 (en) * 2016-03-09 2017-09-14 Msato, Llc Pellet shaped marking round for air rifles and pistols
HU231333B1 (hu) * 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
BR0210075A (pt) * 2001-06-01 2004-08-17 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou distúrbios da debilitação intelectual e de fadiga de vÈo, cessamento de fumar, dependência de nicotina, dores, e para a colite ulcerativa
ES2348282T3 (es) * 2002-04-18 2010-12-02 Astrazeneca Ab Compuestos de tienilo.
US7417049B2 (en) * 2002-04-18 2008-08-26 Astrazeneca Ab Furyl compounds
NZ561993A (en) * 2002-04-18 2008-09-26 Astrazeneca Ab Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors
AU2004276061A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Ligands

Also Published As

Publication number Publication date
WO2007133155A1 (en) 2007-11-22
NO20084915L (no) 2009-02-13
ES2392997T3 (es) 2012-12-17
RU2441007C2 (ru) 2012-01-27
US20110136804A1 (en) 2011-06-09
US7842803B2 (en) 2010-11-30
EP2019831B1 (en) 2012-09-12
AU2007250560A1 (en) 2007-11-22
UY30349A1 (es) 2008-01-02
KR20090007753A (ko) 2009-01-20
AU2007250560B2 (en) 2011-06-23
SA07280244B1 (ar) 2011-06-22
IL195019A0 (en) 2009-08-03
CA2652610A1 (en) 2007-11-22
EP2019831A1 (en) 2009-02-04
ECSP088971A (es) 2009-01-30
MX2008014436A (es) 2008-11-27
TW200813067A (en) 2008-03-16
RU2008143450A (ru) 2010-06-27
US20080139600A1 (en) 2008-06-12
BRPI0711941A2 (pt) 2011-12-13
EP2019831A4 (en) 2010-06-09
AR060914A1 (es) 2008-07-23
JP2009537517A (ja) 2009-10-29

Similar Documents

Publication Publication Date Title
CL2007001405A1 (es) Compuesto correspondiente a (2r)-5 -[5-(morfolin-4-ilmetil)-3-furil]-3 h-espiro[4-azabiciclo[2.2.2]octano-2,2 -furo[2,3-b]piridina], ligando del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso para el tratamiento de la ansiedad, esquizofrenia, alzheimer, adiccion a nicotina, parkinson, entre otras.
Werling et al. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder
PE20081441A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
ECSP099387A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
AR063148A1 (es) Composicion para tratar la dependencia a la nicotina que comprende al menos un antagonista del receptor nicotinico alfa 3 beta 4 y al menos un metabolito de l a nicotina y su uso para preparar un medicamento
FR2897061B1 (fr) Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
IL182034A0 (en) Substituted chroman derivatives, medicaments and use in therapy
CL2007003346A1 (es) Compuestos derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome de abstinencia a una sustancia, tras
JP2009537517A5 (https=)
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
MXPA06000231A (es) Derivados espiro '1-azabiciclo'2.2.2!octan-3,5'-oxazolidin-2'-ona! con afinidad a la alfa7 del receptor nicotinico para acetilcolina.
CO6511240A2 (es) Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia
MY145627A (en) [(1h-indol-5-yl) - heteroaryloxy] - (1-aza-bicyclo[3.3.1] nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders
WO2007016352A3 (en) Oral liquid losartan compositions
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
SI1869038T1 (sl) Substituirane 5,6,7,8-tetrahidro-imidazo(1,2-a)piridin-2-ilaminske spojine in njihova uporaba za pripravo zdravil
BRPI0808377B8 (pt) composto, composição e uso de um composto
CL2012003274A1 (es) Compuestos derivados de espiro[biciclo[2.2.1]heptano-2,1-(ciclobutano o ciclopentano) y espiro- ([biciclo]oct[5]eno o biciclo[2.2.2]octano)-2,1-ciclopentano, moduladores de receptores nicotinicos; composicion farmaceutica; utiles en el tratamiento de enfermedades o condicion ibs-d, oab, adiccion a la nicotina, depresion, entre otros.
WO2014029888A3 (en) Branched or macrocyclic polyamines and uses thereof
CL2008000302A1 (es) Compuestos derivados de 2-oxo-1,4-diazaespiro[4.5]dec-3-en-1-il-acetamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de psicosis, esquizofrenia, demencia y trastorno por falta de atencion.
MY169449A (en) Therapeutic treatment
TW200727904A (en) Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine
WO2009014097A1 (ja) 新規ヒスチジン誘導体
UY27944A1 (es) Terapia de combinacinn para enfermedades hiperproliferativas
TW200633717A (en) Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents